Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Studies

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Overview Studies Clinical Trials
Score 1
2014 pubmed 21 citations

Kisspeptin-10 inhibits the migration of breast cancer cells by regulating epithelial-mesenchymal transition.

Song. Guo-Qing GQ; Zhao. Yi Y

View on DOI View Original Source

Key Findings

  • KP-10 triggers cell death (apoptosis) in breast cancer lines MDA-MB-231 and MDA-MB-157
  • KP-10 reduces the ability of these cancer cells to migrate and invade
  • KP-10 slows tumor growth and improves survival in mouse xenograft models
  • KP-10 blocks formation of new blood vessels in tumors and interferes with EMT

Practical Outcomes

  • At this point the findings are not ready for any DIY or self‑experiment protocols. The peptide was only tested in cells and mice, with no human dosage or safety data, so it cannot be recommended for personal use or longevity regimens.

Summary

Researchers found that a short piece of the protein kisspeptin, called KP-10, can kill breast cancer cells and stop them from spreading in lab dishes and in mice, mainly by blocking a process called EMT that helps cancer cells move. However, the work is early‑stage, done in cell cultures and animal models, and doesn’t give any guidance on safe human use.

Abstract

Breast cancer is the leading cause of cancer-related death in women. Kisspeptin-10 (KP-10) is a shorter fragment of KISS1. In the present study, we demonstrated the antitumor effects of KP-10 on human breast cancer cell lines, MDA-MB-231 and MDA-MB-157, both in vitro and in vivo. KP-10 was observed to induce apoptosis and inhibit the mobility of MDA-MB-231 and MDA-MB-157 cells. Correspondingly, KP-10 suppressed tumor growth in established xenograft tumor models and improved the survival rate of tumor-bearing mice. The formation of intratumoral microvessels was inhibited following treatment with KP-10. Finally, we confirmed that KP-10 inhibited cell mobility via epithelial-mesenchymal transition (EMT). Overall, the present study demonstrated that KP-10 suppressed breast cancer and human umbilical vein endothelial cell (HUVEC) growth both in vivo and in vitro. KP-10 is a novel regulator of EMT in breast cancer cells. However, additional studies are needed to confirm these results in other cell types.

Study Information

Provider

pubmed

Year

2014

Date

2014-11-24T00:00:00.000Z

DOI

10.3892/or.2014.3619

Citations

21

References

26